Braveheart Bio, Inc.'s Quiet Period To Expire on September 15th (NASDAQ:BRVE)

Key Points

• Braveheart Bio’s quiet period ends September 15, potentially allowing IPO underwriters to begin issuing research coverage. The company raised $382.5 million through an offering of 21.25 million shares priced at $18 each.
• Analyst sentiment is broadly positive, with five Buy ratings and one Hold rating. The stock has an average target price of $45.25, including $48 targets from Jefferies and Goldman Sachs.
• Insiders made substantial purchases following the IPO, acquiring 8.75 million shares worth about $157.5 million over the last quarter. BRVE recently opened at $26.74, compared with a 52-week range of $24.31 to $32.00.

Braveheart Bio's (NASDAQ:BRVE - Get Free Report) quiet period will end on Tuesday, September 15th. Braveheart Bio had issued 21,250,000 shares in its public offering on August 6th. The total size of the offering was $382,500,000 based on an initial share price of $18.00. During the company's quiet period, underwriters and any insiders that worked on the IPO are prevented from issuing any earnings forecasts or research reports for the company because of regulations issued by the Securities and Exchange Commission. Following the expiration of the company's quiet period, it's expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

Analyst Ratings Changes

A number of brokerages recently issued reports on BRVE. Wall Street Zen raised Braveheart Bio to a "hold" rating in a research report on Saturday, August 15th. TD Cowen started coverage on Braveheart Bio in a research note on Monday, August 31st. They issued a "buy" rating for the company. Jefferies Financial Group initiated coverage on Braveheart Bio in a report on Monday, August 31st. They issued a "buy" rating and a $48.00 price objective for the company. Cantor Fitzgerald started coverage on shares of Braveheart Bio in a report on Monday, August 31st. They issued an "overweight" rating and a $40.00 target price on the stock. Finally, The Goldman Sachs Group started coverage on shares of Braveheart Bio in a research report on Monday, August 31st. They issued a "buy" rating and a $48.00 price target for the company. Five research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $45.25.

Braveheart Bio Stock Performance

Shares of BRVE opened at $26.74 on Tuesday. Braveheart Bio has a fifty-two week low of $24.31 and a fifty-two week high of $32.00.

Insider Activity

In related news, major shareholder Growth Opportunities F. Forbion acquired 1,680,000 shares of the firm's stock in a transaction on Friday, August 7th. The stock was bought at an average cost of $18.00 per share, with a total value of $30,240,000.00. Following the transaction, the insider owned 10,185,478 shares of the company's stock, valued at $183,338,604. The trade was a 19.75% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, major shareholder Bio Fund Iv L.P. Ah bought 1,100,000 shares of the stock in a transaction on Friday, August 7th. The stock was bought at an average price of $18.00 per share, for a total transaction of $19,800,000.00. Following the completion of the purchase, the insider directly owned 10,232,420 shares in the company, valued at approximately $184,183,560. The trade was a 12.05% increase in their position. The SEC filing for this purchase provides additional information. Insiders bought 8,751,942 shares of company stock worth $157,534,956 over the last quarter.

Braveheart Bio Company Profile

We are a clinical‑stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases. Our lead product candidate, BHB‑1893, is a next-generation oral small‑molecule cardiac myosin inhibitor (“CMI”), that we are developing for the treatment of obstructive HCM (“oHCM”) and non‑obstructive HCM (“nHCM”). Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.